Literature DB >> 8723380

Management of restless legs syndrome with gabapentin (Neurontin)

G A Mellick, L B Mellick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8723380     DOI： 10.1093/sleep/19.3.224

Source DB:  PubMed          Journal:  Sleep        ISSN： 0161-8105            Impact factor:   5.849


× No keyword cloud information.
  13 in total

Review 1.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

3.  Using gabapentin to treat neuropathic pain.

Authors:  H Hays; M A Woodroffe
Journal:  Can Fam Physician       Date:  1999-09       Impact factor: 3.275

4.  A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome.

Authors:  Clete A Kushida; Arthur S Walters; Philip Becker; Stephen G Thein; A Thomas Perkins; Thomas Roth; Daniel Canafax; Ronald W Barrett
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 5.  [Restless legs syndrome, periodic limb movements, and psychopharmacology].

Authors:  S Cohrs; A Rodenbeck; M Hornyak; D Kunz
Journal:  Nervenarzt       Date:  2008-11       Impact factor: 1.214

6.  Gabapentin enacarbil - clinical efficacy in restless legs syndrome.

Authors:  Pinky Agarwal; Alida Griffith; Henry R Costantino; Narendra Vaish
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 7.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Strategies for the treatment of restless legs syndrome.

Authors:  Mark J Buchfuhrer
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

Review 9.  Restless legs syndrome: an update on treatment options.

Authors:  Anthony H V Schapira
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease.

Authors:  Michele A Faulkner
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.